Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ectylurea SCHEMBL1641674 | 1.00 | CRBN (0.39) | CRBNMAPTRAB9ANPSR1 | |
| Ectylurea SCHEMBL8189887 | 1.00 | CRBN (0.39) | CRBNMAPTRAB9ANPSR1 | |
| SCHEMBL20317510 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL29415851 | 0.74 | CRBN (0.31) | CRBN | |
| SCHEMBL19011343 | 0.73 | — | — | |
| SCHEMBL28716275 | 0.73 | — | — | |
| SCHEMBL27460647 | 0.73 | CRBN (0.43) | CRBNMAPTRAB9ANPSR1 | |
| SCHEMBL11372614 | 0.72 | — | — | |
| SCHEMBL4742487 | 0.72 | — | — | |
| SCHEMBL28719312 | 0.71 | MMP1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770514-B2 | Tamper-resistant pharmaceutical dosage forms | ExxPharma Therapeutics LLC (US) | 2017-09-26 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150064250-A1 | Tamper-Resistant Pharmaceutical Dosage Forms | ExxPharma Therapeutics LLC (US) | 2015-03-05 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-RE38934-E1 | Method and reagents for N-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-01-10 | — | — | US | claimed |
| US-20040167358-A1 | Method and reagents for N-alkylating ureides | GUTMAN DANIELA (IL) | 2004-08-26 | — | — | US | claimed |
| EP-1027339-B1 | METHOD AND REAGENTS FOR N-ALKYLATING UREIDES | TARO PHARMA IND (IL) | 2004-01-02 | — | — | EP | claimed |
| US-20030018080-A1 | N-methoxymethyl-5,5-diphenylbarbituric acid | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-23 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-1027339-A1 | METHOD AND REAGENTS FOR N-ALKYLATING UREIDES | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2000-08-16 | — | — | EP | claimed |
| US-6093820-A | REACTING AN IMIDE WITH A (SUBSTITUTED)ALKOXYALKYLSULFONIC ACID ESTER TO FORM A N-ALKOXYALKYL IMIDE SUCH AS METHOXYMETHYL ETHOSUXIMIDE; ADMINISTERING AS ANTICONVULSANT, ANTIANXIETY AGENT AND MUSCLE RELAXANT | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-07-25 | — | — | US | claimed |
| WO-1999018084-A1 | METHOD AND REAGENTS FOR N-ALKYLATING UREIDES | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1999-04-15 | — | — | WO | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| US-20240262982-A1 | SILANE COUPLING AGENT COMPOSITION AND RUBBER COMPOSITION CONTAINING SAME | ENEOS CORPORATION (JP) | 2024-08-08 | — | — | US | disclosed |
| CN-118339274-A | Brandy replica | 艾娃食品实验室股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4349903-A1 | SILANE COUPLING AGENT COMPOSITION AND RUBBER COMPOSITION COMPRISING SAME | ENEOS Corporation (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022160065-A1 | FORMULATIONS INCLUDING DIHYDROHONOKIOL | BETTERLIFE PHARMA INC. (CA) | 2022-08-04 | — | — | WO | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FIRST WAVE BIO, INC. | 2021-12-30 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| WO-2021188564-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210114973-A1 | PHARMACEUTICAL FORMULATIONS | FIRST WAVE BIO, INC. | 2021-04-22 | — | — | US | disclosed |
| WO-2021076922-A1 | PHARMACEUTICAL FORMULATIONS | FIRST WAVE BIO, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-10980756-B1 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-08-27 | — | — | US | disclosed |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197310-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-10583086-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | disclosed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| CN-109562137-A | Methods and compositions for treating conditions associated with abnormal inflammatory responses | 第波生物公司 | 2019-04-02 | — | — | CN | disclosed |
| US-10231938-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3344274-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Bio, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| US-10010620-B2 | Tamper-resistant pharmaceutical dosage forms and process for making same | ExxPharma Therapeutics LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180071219-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180028449-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2018-02-01 | — | — | US | disclosed |
| US-9770514-B2 | Tamper-resistant pharmaceutical dosage forms | ExxPharma Therapeutics LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-9682043-B2 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170079920-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2017-03-23 | — | — | US | disclosed |
| WO-2017040864-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Biopharma (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20160235675-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-1807033-B1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMA (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160175454-A1 | Tamper-Resistant Pharmaceutical Dosage Forms and Process for Making Same | NEUROCRINE BIOSCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160128949-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20150359746-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2015-12-17 | — | — | US | disclosed |
| US-20150290134-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | NEXBIO, INC. | 2015-10-15 | — | — | US | disclosed |
| US-9155712-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| CN-104758253-A | Technology for preparation of macromolecular microspheres | NEXBIO INC | 2015-07-08 | — | — | CN | disclosed |
| US-20150157578-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| WO-2015034846-A1 | TAMPER-RESISTANT PHARMACEUTICAL DOSAGE FORMS AND PROCESS FOR MAKING SAME | ExxPharma Therapeutics LLC (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150064251-A1 | Tamper Resistant Dosage Form Composition And Process Of Making The Same | ExxPharma Therapeutics LLC | 2015-03-05 | — | — | US | disclosed |
| US-20150064250-A1 | Tamper-Resistant Pharmaceutical Dosage Forms | ExxPharma Therapeutics LLC (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150050713-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8815281-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140134150-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | ANSUN BIOPHARMA, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| CN-103784408-A | Technology for the preparation of microparticles | ANSUN BIOPHARMA INC | 2014-05-14 | — | — | CN | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140099696-A1 | Technology for the Preparation of Microparticles | ANSUN BIOPHARMA, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8623419-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8591941-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8414914-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| CN-101534809-B | Use of substituted 2-amino-1, 2,3, 4-tetrahydronaphthalenes for producing medicaments for the prophylaxis, alleviation and/or treatment of various types of pain | UCB PHARMA GMBH | 2013-03-13 | — | — | CN | disclosed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120308644-A1 | Compositions for mucosal delivery of agents | ARCHIMEDES LABORATORIES, INC. | 2012-12-06 | — | — | US | disclosed |
| US-20120269881-A9 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-8252323-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2032128-B1 | USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION, ALLEVIATION AND/OR TREATMENT OF VARIOUS TYPES OF PAIN | UCB PHARMA GMBH (DE) | 2012-08-15 | — | — | EP | disclosed |
| EP-1768647-B1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT | VIRUN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120165762-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120141590-A1 | Technology for the Preparation of Microparticles | MALAKHOV MICHAEL (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120116062-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | ANSUN BIOPHARMA, INC. | 2012-05-10 | — | — | US | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| CN-101005828-B | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents | VIRUN INC | 2012-01-11 | — | — | CN | disclosed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| US-20110117184-A1 | Compositions for mucosal delivery of agents | VIRUN, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110104281-A1 | METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND | UCB PHARMA GMBH (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110097384-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7906140-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| CN-101848704-A | Techniques for preparing microparticles | NEXBIO INC | 2010-09-29 | — | — | CN | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100166874-A1 | Technology for Preparation of Macromolecular Microspheres | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-01 | — | — | US | disclosed |
| EP-2173327-A2 | TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES | Nexbio, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100047345-A1 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM FOR HYDROMORPHONE | CROWLEY MICHAEL M | 2010-02-25 | — | — | US | disclosed |
| CN-101534809-A | Use of substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes for producing medicaments for the prophylaxis, alleviation and/or treatment of various types of pain | SANOL ARZNEI SCHWARZ GMBH (DE) | 2009-09-16 | — | — | CN | disclosed |
| EP-2068840-A2 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB International SRL (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2049087-A2 | HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM | LAB International SRL (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090098207-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| CN-101404980-A | Preparation Technology of Macromolecular Microspheres | NEXBIO INC (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-2032128-A1 | USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION, ALLEVIATION AND/OR TREATMENT OF VARIOUS TYPES OF PAIN | SCHWARZ PHARMA AG (DE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009015286-A2 | TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES | NEXBIO, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| EP-1981483-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | Nexbio, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1896042-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| CN-101237838-A | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX INC (US) | 2008-08-06 | — | — | CN | disclosed |
| US-20080075771-A1 | HYDROPHILIC OPIOID ABUSE DETERRENT DELIVERY SYSTEM USING OPIOID ANTAGONISTS | AKELA PHARMA SRL (BB) | 2008-03-27 | — | — | US | disclosed |
| US-20080075770-A1 | HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM | AKELA PHARMA SRL (BB) | 2008-03-27 | — | — | US | disclosed |
| US-20080075768-A1 | HYDROPHOBIC OPIOID ABUSE DETERRENT DELIVERY SYSTEM USING OPIOID ANTAGONISTS | AKELA PHARMA SRL (BB) | 2008-03-27 | — | — | US | disclosed |
| US-20080069871-A1 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | AKELA PHARMA SRL (BB) | 2008-03-20 | — | — | US | disclosed |
| EP-1896042-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1895959-A1 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2008011595-A9 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNAT SRL (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008011595-A2 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNATIONAL SRL (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011596-A2 | HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNATIONAL SRL (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080020032-A1 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM FOR HYDROMORPHONE | AKELA PHARMA SRL (BB) | 2008-01-24 | — | — | US | disclosed |
| US-20080008748-A1 | METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND | UCB PHARMA GMBH (DE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007147556-A1 | USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION, ALLEVIATION AND/OR TREATMENT OF VARIOUS TYPES OF PAIN | SCHWARZ PHARMA AG (DE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007114881-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | NEXBIO, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070190163-A1 | Technology for preparation of macromolecular microspheres | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTE OF HEALTH | 2007-08-16 | — | — | US | disclosed |
| CN-101005828-A | Compositions comprising a mucoadhesive protein and an activeprinciple for mucosal delivery of said agents | VIRUN INC (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1807033-A2 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| US-20070110685-A1 | Combination therapy for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2007-05-17 | — | — | US | disclosed |
| EP-1768647-A1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT | Virun, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006138518-A1 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138372-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060286177-A1 | Methods and reagents for the treatment of inflammatory disorders | COMBINATORX, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| EP-1727520-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-7122198-B1 | Fast dissolving composition with prolonged sweet taste | PANACEA BIOTEC LIMITED (IN) | 2006-10-17 | — | — | US | disclosed |
| US-7115373-B2 | Diagnosing allergies via measuring expression of nuclear orphan receptor (NOR-1 receptor) gene; identifying modulators for treating atopic dermatitis | GENOX RESEARCH, INC. (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006044206-A2 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060078604-A1 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| US-7026360-B1 | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients | INPHARMA S.A. (CH) | 2006-04-11 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006009825-A1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENTS | VIRUN, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-RE38934-E1 | Method and reagents for N-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-01-10 | — | — | US | disclosed |
| WO-2006001815-A1 | ACTIVE AGENTS USING LIPOSOME MACRO-BEADS | SUVANPRAKORN PICHIT (TH) | 2006-01-05 | — | — | WO | disclosed |
| EP-1021204-B1 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMA (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050281772-A1 | Compositions for mucosal delivery of agents | VIRUN, INC. | 2005-12-22 | — | — | US | disclosed |
| US-20050181041-A1 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1342718-B1 | N-alkylated ureides | TARO PHARMA IND (IL) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005055983-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2005-06-23 | — | — | WO | disclosed |
| US-6906079-B2 | Method and reagents for N-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2005-06-14 | — | — | US | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| CN-1178699-C | Pharmaceutical Compsns. contg. compounds with activity for enhancement of absorption of active ingredients | — | 2004-12-08 | — | — | CN | disclosed |
| US-20040224012-A1 | Topical application and methods for administration of active agents using liposome macro-beads | BIOPHILE CORPORATION LTD. (TH) | 2004-11-11 | — | — | US | disclosed |
| US-20040167358-A1 | Method and reagents for N-alkylating ureides | GUTMAN DANIELA (IL) | 2004-08-26 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-20040018241-A1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| EP-1027339-B1 | METHOD AND REAGENTS FOR N-ALKYLATING UREIDES | TARO PHARMA IND (IL) | 2004-01-02 | — | — | EP | disclosed |
| US-6664262-B2 | N-methoxymethyl-5,5-diphenylbarbituric acid | TARO PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2003-12-16 | — | — | US | disclosed |
| US-6638528-B1 | Pressure-sensitive adhesive matrix comprising blend of polyacrylate, polysiloxane, polyisobutylene, polyisoprene, polyamide or polystyrene; and insoluble, non-adhesive ethyl cellulose; polyvinylpyrrolidone crystallization inhibitor | NOVEN PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| EP-1342718-A1 | Method and reagents for n-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2003-09-10 | — | — | EP | disclosed |
| US-6562363-B1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| WO-2003030818-A2 | ACTIVE AGENTS USING LIPOSOME BEADS | SUVANPRAKORN PICHIT (TH) | 2003-04-17 | — | — | WO | disclosed |
| US-20030068365-A1 | Compositions and methods for administration of active agents using liposome beads | BIOPHILE CORPORATION, LTD. (TH) | 2003-04-10 | — | — | US | disclosed |
| US-20030018080-A1 | N-methoxymethyl-5,5-diphenylbarbituric acid | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-23 | — | — | US | disclosed |
| EP-1235561-A2 | FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE | Panacea Biotec Limited (IN) | 2002-09-04 | — | — | EP | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020004065-A1 | Compositions and methods to effect the release profile in the transdermal administration of active agents | KANIOS DAVID (US) | 2002-01-10 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| WO-2001039749-A2 | FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE | PANACEA BIOTEC LIMITED (IN) | 2001-06-07 | — | — | WO | disclosed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | disclosed |
| US-6221383-B1 | BLEND OF AT LEAST TWO POLYMERS, OR AT LEAST ONE POLYMER AND A SOLUBLE POLYVINYLPYRROLIDONE, IN COMBINATION WITH A DRUG PROVIDES A PRESSURE-SENSITIVE ADHESIVE COMPOSITION FOR A TRANSDERMAL DRUG DELIVERY SYSTEM | NOVEN PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-1027339-A1 | METHOD AND REAGENTS FOR N-ALKYLATING UREIDES | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2000-08-16 | — | — | EP | disclosed |
| EP-1021204-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6093820-A | REACTING AN IMIDE WITH A (SUBSTITUTED)ALKOXYALKYLSULFONIC ACID ESTER TO FORM A N-ALKOXYALKYL IMIDE SUCH AS METHOXYMETHYL ETHOSUXIMIDE; ADMINISTERING AS ANTICONVULSANT, ANTIANXIETY AGENT AND MUSCLE RELAXANT | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-07-25 | — | — | US | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1999018084-A1 | METHOD AND REAGENTS FOR N-ALKYLATING UREIDES | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1999-04-15 | — | — | WO | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0129285-B1 | PENETRATING TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING N-(2-HYDROXYETHYL)PYRROLIDONE | THE PROCTER & GAMBLE COMPANY (US) | 1991-05-15 | — | — | EP | disclosed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | disclosed |
| US-4537776-A | PERCUTANEOUS DELIVERY OF ANTIINFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0129285-A2 | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl)pyrrolidone | THE PROCTER & GAMBLE COMPANY (US) | 1984-12-27 | — | — | EP | disclosed |
| EP-0129284-A2 | Improved penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one | THE PROCTER & GAMBLE COMPANY (US) | 1984-12-27 | — | — | EP | disclosed |
| US-4346101-A | NON-SEDATING | THE UPJOHN COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| US-4215114-A | Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be | THE UPJOHN COMPANY (US) | 1980-07-29 | — | — | US | disclosed |
| US-4212878-A | Phenylacetamide derivative analgesics | THE UPJOHN COMPANY (US) | 1980-07-15 | — | — | US | disclosed |
| US-4197308-A | Analgesic N-(2-heterocyclic-amino cycloaliphatic) benzamides | THE UPJOHN COMPANY (US) | 1980-04-08 | — | — | US | disclosed |
| US-4192885-A | Analgesic N-{2-[N'-(2-furylmethyl and 2-thienyl-methyl)-N'-alkylamino]cycloaliphatic}cyanobenzamides | THE UPJOHN COMPANY (US) | 1980-03-11 | — | — | US | disclosed |
| US-4167567-A | Antihypertensive 4-aminoquinolines | THE UPJOHN COMPANY (US) | 1979-09-11 | — | — | US | disclosed |
| US-4166853-A | Antihypertensive 7-trifluoromethyl-4-aminoquinolones | THE UPJOHN COMPANY (US) | 1979-09-04 | — | — | US | disclosed |
| US-4159331-A | Antihypertensive 4-aminoquinolines | THE UPJOHN COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4153717-A | 260/332.2 R | THE UPJOHN COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
| US-4152459-A | Analgesic N-2-(aminocycloaliphatic)-hydroxy, alkoxy and (allylic)alkenyloxy-benzamides | THE UPJOHN COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
| US-4148914-A | Analgesic N-(2-aminocyclo aliphatic)cyanobenzamides | THE UPJOHN COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4145435-A | 2-AMINOCYCLOALIPHATIC AMIDE COMPOUNDS | THE UPJOHN COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
| US-4140775-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
| US-4098904-A | ANALGESIC N-(2-AMINOCYCLOALIPHATIC)BENZAMIDES | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4057633-A | ANTIANXIETY, HYPOTENSIVE | THE UPJOHN COMPANY (US) | 1977-11-08 | — | — | US | disclosed |
| US-4025629-A | HYPOTENSIVES, ANTIANXIETY | THE UPJOHN COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
| US-3992382-A | HYPERTENSION AND ANXIETY TREATMENT | THE UPJOHN COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3992382-A | HYPERTENSION AND ANXIETY TREATMENT | THE UPJOHN COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (38 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FH, CS, ECHS1 | CRBN 3965/4885MAPT 971/4885RAB9A 2223/4885 |
| US-20110104281-A1 | METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND | AADAT, MTPN, MYOF | CRBN 4687/4885MAPT 1135/4885RAB9A 2926/4885 |
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CRBN 2138/4885MAPT 1721/4885RAB9A 1754/4885 |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CRBN 3934/4885MAPT 954/4885RAB9A 2185/4885 |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CRBN 3925/4885MAPT 969/4885RAB9A 2177/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CRBN 3934/4885MAPT 954/4885RAB9A 2185/4885 |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CRBN 3925/4885MAPT 969/4885RAB9A 2177/4885 |
| US-20210114973-A1 | PHARMACEUTICAL FORMULATIONS | NCSTN, CACNA1B, CACNA1A | CRBN 2839/4885MAPT 389/4885RAB9A 741/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | CRBN 1717/4885MAPT 1657/4885RAB9A 2303/4885 |
| US-20070110685-A1 | Combination therapy for the treatment of immunoinflammatory disorders | SERPINC1, SERPINA6, IL36G | CRBN 3667/4885MAPT 231/4885RAB9A 3277/4885 |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | CRBN 3934/4885MAPT 954/4885RAB9A 2185/4885 |
| US-20030018080-A1 | N-methoxymethyl-5,5-diphenylbarbituric acid | MGMT, ALKBH3, ALKBH5 | CRBN 2070/4885MAPT 3277/4885RAB9A 4198/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CRBN 3925/4885MAPT 969/4885RAB9A 2177/4885 |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CRBN 3965/4885MAPT 971/4885RAB9A 2223/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | CRBN 1152/4885MAPT 704/4885RAB9A 424/4885 |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CRBN 3934/4885MAPT 954/4885RAB9A 2185/4885 |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | CRBN 3925/4885MAPT 969/4885RAB9A 2177/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | CRBN 3925/4885MAPT 969/4885RAB9A 2177/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CRBN 1292/4885MAPT 845/4885RAB9A 610/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | CRBN 1292/4885MAPT 845/4885RAB9A 610/4885 |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CRBN 3962/4885MAPT 957/4885RAB9A 2227/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CRBN 1299/4885MAPT 753/4885RAB9A 648/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | CRBN 3034/4885MAPT 4304/4885RAB9A 3125/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | CRBN 1299/4885MAPT 753/4885RAB9A 648/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CRBN 1299/4885MAPT 753/4885RAB9A 648/4885 |
| US-20040167358-A1 | Method and reagents for N-alkylating ureides | MGMT, ETV6, ALKBH3 | CRBN 1168/4885MAPT 3104/4885RAB9A 4394/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CRBN 3925/4885MAPT 969/4885RAB9A 2177/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | CRBN 3551/4885MAPT 1112/4885RAB9A 2086/4885 |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CRBN 3925/4885MAPT 969/4885RAB9A 2177/4885 |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CRBN 3925/4885MAPT 969/4885RAB9A 2177/4885 |
| US-20060286177-A1 | Methods and reagents for the treatment of inflammatory disorders | TNF, CCL11, IL5 | CRBN 1463/4885MAPT 1711/4885RAB9A 4374/4885 |
| US-10980756-B1 | Methods of treatment | ACE2, ACE, SI | CRBN 1292/4885MAPT 845/4885RAB9A 610/4885 |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CRBN 3925/4885MAPT 969/4885RAB9A 2177/4885 |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CRBN 3965/4885MAPT 971/4885RAB9A 2223/4885 |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CRBN 3965/4885MAPT 971/4885RAB9A 2223/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CRBN 3965/4885MAPT 971/4885RAB9A 2223/4885 |
| US-20080008748-A1 | METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND | AADAT, MTPN, MYOF | CRBN 4722/4885MAPT 812/4885RAB9A 2943/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CRBN 2396/4885MAPT 2239/4885RAB9A 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.